Kissei stock faces Tavneos charges as approval risk escalates

Kissei Pharmaceutical said on October 29 that it will record extraordinary losses linked to Tavneos, its vasculitis drug, as Japanese regulators pursue administrative proceedings that could lead to a withdrawal of the product's marketing approval. The update was reported by Jiho.

Tavneos weighs on the bottom line

Kissei raised its forecasts for sales, operating profit and ordinary profit for the six months ended September 30, 2026. The company nevertheless lowered its outlook for profit attributable to owners because of extraordinary losses associated with Tavneos-related assets.

The regulatory backdrop remains unsettled. According to JapanIR, Kissei said the Japanese Pharmaceutical Affairs and Food Sanitation Council had raised doubts about the reliability of submitted materials. Medical institutions were asked not to begin new Tavneos treatments, while alternative treatment or discontinuation should be considered for existing patients. The company said the business impact was still under review.

Investor focus turns to November

Kissei is expected to update its full-year guidance when it announces interim results on November 4. For investors, the key issues are the scale of the Tavneos-related charge, the possible effect of further regulatory action and whether growth in other products can offset the drug's deterioration.

Tokyo trading data showed Kissei at JPY 3,845 at 09:38 Japan time on October 30, 2026, up JPY 130, or 3.50 percent, from the previous close. This is a Tokyo Stock Exchange quote in yen rather than a euro-denominated German-market quote.

Japan's pharmaceutical sector remains sensitive to regulatory decisions and product-safety developments. Broader market context is available through the Nikkei 225 topic page.

Further reports and analyses on Kissei stock are available on the Kissei stock topic page.